DERM Dermira Inc.

8.04
-0.18  -2%
Previous Close 8.23
Open 8.27
Price To Book 29.8
Market Cap 438,622,893
Shares 54,521,180
Volume 1,408,771
Short Ratio
Av. Daily Volume 1,275,095
Stock charts supplied by TradingView

NewsSee all news

  1. Dermira to Participate in the Guggenheim Healthcare Talks Idea Forum, Neuro/Immunology Day

    Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin

  2. Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin

  3. Dermira Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    - QBREXZA® (glycopyrronium) cloth net product sales of $10.2M - Phase 3 lebrikizumab program initiated in adult and adolescent patients with moderate-to-severe atopic dermatitis - Conference call today at 1:30 p.m.

  4. Dermira to Report Third Quarter 2019 Results and Host Conference Call on Tuesday, November 5, 2019

    Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin

  5. Dermira to Present Data from Phase 2b Study of Lebrikizumab in Patients with Atopic Dermatitis at Fall Clinical Dermatology Conference

    - Detailed primary results of lebrikizumab Phase 2b study to be presented at the Fall Clinical Dermatology Conference - Data reflect potential of lebrikizumab to offer best-in-disease combination of safety, efficacy,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data released March 5, 2018 - failed to meet all co-primary endpoints.
Olumacostat glasaretil (DRM01)
Acne
Approval announced June 29, 2018.
Glycopyrronium tosylate
Primary axillary hyperhidrosis
Phase 3 trial initiation announced October 9, 2019. Top-line data due 1H 2021.
Lebrikizumab
Atopic Dermatitis
Proof of concept initiation announced February 22, 2019 with data due 2H 2019.
QBREXZA (glycopyrronium)
Primary palmar hyperhidrosis

Latest News

  1. Dermira to Participate in the Guggenheim Healthcare Talks Idea Forum, Neuro/Immunology Day

    Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin

  2. Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin

  3. Dermira Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    - QBREXZA® (glycopyrronium) cloth net product sales of $10.2M - Phase 3 lebrikizumab program initiated in adult and adolescent patients with moderate-to-severe atopic dermatitis - Conference call today at 1:30 p.m.

  4. Dermira to Report Third Quarter 2019 Results and Host Conference Call on Tuesday, November 5, 2019

    Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin

  5. Dermira to Present Data from Phase 2b Study of Lebrikizumab in Patients with Atopic Dermatitis at Fall Clinical Dermatology Conference

    - Detailed primary results of lebrikizumab Phase 2b study to be presented at the Fall Clinical Dermatology Conference - Data reflect potential of lebrikizumab to offer best-in-disease combination of safety, efficacy,

  6. Dermira Announces Initiation of Phase 3 Program Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis

    - Two identical Phase 3 monotherapy studies expected to enroll a total of approximately 800 adult and adolescent patients ages 12 and older - Topline results from the 16-week induction period expected in the first

  7. Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin

  8. Dermira to Participate in the 2019 Cantor Global Healthcare Conference

    Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin

  9. Dermira to Participate in Upcoming Investor Conferences

    Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin